Saxagliptin overview: special focus on safety and adverse effects

Bibliography

• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;May132(6):2131-57
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;Jan29(1):46-52
   PubMed Web of Science ®Google Scholar
• Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;Nov30(11):600-7
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;Oct26(10):2929-40
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;Nov11368(9548):1696-705
   PubMed Web of Science ®Google Scholar
• Frederich R, McNeill R, Berglind N, The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr 2012;Jul244(1):36
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;May10(5):376-8
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E, Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;Oct25(10):2401–
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfutzner A, Paz-Pacheco E, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;Jun11(6):611-22
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;Sep32(9):1649-55
   PubMed Web of Science ®Google Scholar
• Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin (SAXA) 5 mg is superior to uptitrating metformin extended release (MET XR) in type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control on a stable dose of MET XR 1500 mg. Diabetes 2011;60:A279
   Google Scholar
• Scheen AJ. Saxagliptin plus metformin combination therapy. Expert Rev Endocrinol Metab 2012;7(2):151-64
   PubMedGoogle Scholar
• Chacra AR, Tan GH, Apanovitch A, Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;Sep63(9):1395-406
   PubMed Web of Science ®Google Scholar
• Goke B, Gallwitz B, Eriksson J, D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;Nov64(12):1619-31
   PubMed Web of Science ®Google Scholar
• Karyekar C, Donovan M, Allen E, Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med 2011;123(4):63-70
   PubMed Web of Science ®Google Scholar
• Barnett AH, Charbonnel B, Donovan M, Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012;28(4):513-23
   PubMed Web of Science ®Google Scholar
• Fakhoury WKH, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86(1):44-57
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376(9739):431-9
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;Jul3071(11):1441-67
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;Aug12(8):648-5
   PubMed Web of Science ®Google Scholar
• Fura A, Khanna A, Vyas V, Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009;Jun37(6):1164-71
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs 2008;Dec11(12):906-17
   PubMed Web of Science ®Google Scholar
• Burkey BF, Hoffmann PK, Hassiepen U, Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;Nov10(11):1057-61
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;Oct54(10):2988-94
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49(9):573-88
   PubMed Web of Science ®Google Scholar
• Patel CG, Li L, Girgis S, Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol 2011;3(1):13-25
   Google Scholar
• Williams-Herman D, Engel SS, Round E, Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
   PubMed Web of Science ®Google Scholar
• Goke B, Gallwitz B, Eriksson J, Saxagliptin vs glipizide as add-on therapy to metformin for type 2 diabetes mellitus (T2DM): Long-term safety and efficacy. Diabetes 2011;60:A305
   Google Scholar
• Rosenstock J, Gross JL, Salinas CAA, Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes. Diabetes 2011;60:A298
   PubMed Web of Science ®Google Scholar
• Goke B, Gallwitz B, Eriksson J, Saxagliptin vs glipizide as add-on therapy to metformin for type 2 diabetes mellitus (T2DM): long-term safety and efficacy. Diabetes 2011;60:A305
   Google Scholar
• Barnett AH, Charbonnel B, Li J, Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Diabetologia 2011;54:S108-9
   Web of Science ®Google Scholar
• Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl 3):57-64
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25(4):1019-27
   PubMed Web of Science ®Google Scholar
• Engel SS, Williams-Herman DE, Golm GT, Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64(7):984-90
   PubMed Web of Science ®Google Scholar
• Pan CY, Yang W, Tou C, Efficacy and safety of saxagliptin in drug-naive asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012;28(3):268-75
   PubMed Web of Science ®Google Scholar
• Goossen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012; Epub ahead of print
   Google Scholar
• Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 2008;82(Suppl 1):S75-9
   Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;Jan16287(3):360-72
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Setter SM, Gates BJ, Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus. Consult Pharm 2009;Jan24(1):45-63
   PubMedGoogle Scholar
• Nowicki M, Rychlik I, Haller H, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;Jun13(6):523-32
   PubMed Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50(4):253-65
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol 2012;8(3):383-94
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;May122(3):16-27
   PubMed Web of Science ®Google Scholar
• Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;Dec94(12):4810-19
   PubMed Web of Science ®Google Scholar